Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 0

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
PELTHOS THERAPEUTICS
INC. 

CONDENSED CONSOLIDATED
BALANCE SHEETS

    June
    30, 2025

    December
    31, 2024

    (Unaudited)

    ASSETS

    CURRENT ASSETS

    Cash
     
    $
    59,172

    $
    513,443

    Prepaid expenses

    12,341

    65,300

    Due from Chromocell
    Corporation

    40,400

    40,400

    Deferred offering
    costs

    710,937

    750,000

    TOTAL CURRENT ASSETS

    822,850

    1,369,143

    TOTAL ASSETS
     
    $
    822,850

    $
    1,369,143

    LIABILITIES
    AND STOCKHOLDERS’ DEFICIT

    CURRENT LIABILITIES

    Accounts payable and
    accrued expenses
     
    $
    4,988,822

    $
    1,897,127

    Accrued compensation

    23,636

    —

    Loan payable, net
    of debt discount

    2,172,819

    2,054,202

    Loan payable - related
    party, net of debt discount

    131,868

    131,868

    TOTAL CURRENT LIABILITIES

    7,317,145

    4,083,197

    TOTAL LIABILITIES

    7,317,145

    4,083,197

    COMMITMENTS AND
    CONTINGENCIES

    STOCKHOLDERS’
    DEFICIT

    Preferred stock
    Series A, $0.0001 par value, 700,000 shares authorized, no shares issued and outstanding as of June
    30, 2025 and December 31, 2024, respectively

    —

    —

    Preferred stock
    Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and
    outstanding as of June 30, 2025 and December 31, 2024, respectively

    —

    —

    Common stock, $0.0001 par
    value,